StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the stock.
Moleculin Biotech Price Performance
Shares of NASDAQ MBRX opened at $2.36 on Friday. The business has a 50 day simple moving average of $2.50 and a 200 day simple moving average of $3.81. Moleculin Biotech has a 52 week low of $2.12 and a 52 week high of $15.75.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.13). Equities analysts expect that Moleculin Biotech will post -8.6 earnings per share for the current year.
Hedge Funds Weigh In On Moleculin Biotech
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Recommended Stories
- Five stocks we like better than Moleculin Biotech
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- Trading Halts Explained
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- 3 REITs to Buy and Hold for the Long Term
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.